



## NUCLIDIUM Announces Issuance of New U.S. Patent Covering its <sup>61</sup>Cu-based Radiodiagnostic Program for PSMA-positive Prostate Cancer

Basel, Switzerland / Munich, Germany, January 26, 2026 – [NUCLIDIUM AG](#), a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced that U.S. Patent No. 12,527,885 has been granted by the United States Patent and Trademark Office (USPTO). This critical achievement strengthens and extends the scope of the intellectual property portfolio for NUCLIDIUM's NU101 radiotheranostic program. The patent protects the Copper-61 based diagnostic as well as its use in combination with the Copper-67 based therapeutic in a theranostic setting. NUCLIDIUM's NU101 theranostic program was designed to utilize high-radiopure Copper-61 to diagnose and Copper-67 to treat Prostate-Specific Membrane Antigen (PSMA)-positive tumors, making it a true theranostic by using the same radiometal.

"This patent grant validates the scientific innovation behind our copper-based radiopharmaceutical platform and strengthens our ability to advance differentiated therapies across our pipeline. Robust intellectual property is critical as we accelerate the clinical development of our best-in-class copper-based radiotheranostic programs and strive to deliver new treatment options for patients with difficult-to-treat cancers, including prostate and metastatic breast cancer," said **Leila Jaafar, PhD, CEO and Co-Founder of NUCLIDIUM**.

The issued patent covers the composition of matter and methods of using the radiodiagnostic <sup>61</sup>Cu-NU101 in radioimaging, including Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) imaging of PSMA-positive tumors, as well as the subsequent combination with the therapeutic pair <sup>67</sup>Cu-NU101. Over 90% of prostate tumors express PSMA<sup>1</sup>, rendering this surface-level antigen an attractive target for cancer diagnosis and treatment. NUCLIDIUM's <sup>61</sup>Cu-based NU101 diagnostic component allows for delayed imaging, in which even very small metastases can be detected. Based on these imaging data, the <sup>67</sup>Cu-based NU101 therapeutic can enable targeted treatment with a potentially reduced radiation burden for the patient.

The diagnostic component <sup>61</sup>Cu-NU101 is currently in clinical evaluation. Data from a Phase 1 trial [showed](#) favorable imaging performance for <sup>61</sup>Cu-NU101 in PSMA-positive prostate cancer compared with an FDA-approved standard of care diagnostic imaging agent. <sup>61</sup>Cu-NU101 visualized additional lesions in 50% of the patients which were not seen with the FDA-approved standard of care agent and demonstrated favorable tumor-to-background ratios. The number of detected lesions on the <sup>61</sup>Cu-NU101 PET increased for up to 4 hours after administration, highlighting the diagnostic benefits of <sup>61</sup>Cu-NU101's 3.3-hour half-life and high positron yield. Based on these favorable data, NUCLIDIUM is planning to initiate Phase 2 clinical trials for the NU101 diagnostic and therapeutic pair in 2026.

### About NUCLIDIUM

NUCLIDIUM AG is a clinical-stage biotechnology company pioneering the development of next-generation copper-based radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging copper isotopes – Copper-61 for diagnostics and Copper-67 for therapeutics – NUCLIDIUM is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics. The company's operations in Switzerland and Germany combine innovative chemistry, deep clinical expertise, and strategic manufacturing capabilities to deliver scalable, accessible, and clinically superior theranostic solutions to patients worldwide. NUCLIDIUM is committed to expanding the reach and efficacy of radiotheranostics, including addressing critical unmet medical needs in oncology and women's health.



For more information, please contact:

**NUCLIDIUM**

Leila Jaafar, PhD, CEO

Email: [info@nuclidium.com](mailto:info@nuclidium.com)

**Investor/Media Contact NUCLIDIUM**

Trophic Communications

Stephanie May

Email: [nuclidium@trophic.eu](mailto:nuclidium@trophic.eu)

Phone: +49 171 1855682

---

<sup>1</sup> Calais J, Czernin J. PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy. J Nucl Med. 2021 Nov;62(11):1489-1491. doi: 10.2967/jnumed.121.263159. PMID: 34725231; PMCID: PMC8612346.